Amended Quarterly Report (10-q/a)
May 16 2019 - 3:26PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q/A
Amendment No. 1
(Mark
One)
[X]
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For
the quarterly period ended March 31, 2019
or
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For
the transition period from _________to___________
Commission
File Number: 000-51353
PROTAGENIC
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
06-1390025
|
|
(State or other
jurisdiction of
|
|
(I.R.S. Employer
|
|
incorporation
or organization)
|
|
Identification
No.)
|
149
Fifth Avenue, Suite 500, New York, New York 10010
(Address
of Principal Executive Office) (Zip Code)
(212)
994-8200
Registrant’s
Telephone Number Including Area Code
Securities registered pursuant to Section
12(b) of the Act:
|
Title of each
class
|
|
Ticker symbol(s)
|
|
Name of each
exchange on which registered
|
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate
by check mark whether the registrant has submitted electronically every Interactive
Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting
company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”,
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
|
[ ]
|
Accelerated filer
|
[ ]
|
|
Non-accelerated filer
|
[X]
|
Smaller reporting company
|
[X]
|
|
Emerging Growth Company
|
[ ]
|
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 126-2 of the Exchange Act). [ ] Yes [X]
No
As
of May 15, 2019, there were 10,261,419 shares of common stock outstanding.
EXPLANATORY
NOTE
The
sole purpose of this Amendment No. 1 to the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2019 of
Protagenic
Therapeutics, Inc. (the Company”) filed with the Securities and Exchange Commission on May 15, 2019 (the “Form 10-Q”)
is to furnish Exhibits 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T.
No
other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of
the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update
in any way disclosures made in the original Form 10-Q.
Item
6. Exhibits
The
following is a complete list of exhibits filed as part of this Form 10-Q/A. Exhibit numbers correspond to the numbers in the Exhibit
Table of Item 601 of Regulation S-K.
|
(€)
|
- Filed herewith.
|
|
(*)
|
- Furnished, not filed, in accordance with item
601(32)(ii) of Regulation S-K.
|
SIGNATURES
Pursuant
to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
|
Date: May 16, 2019
|
Protagenic
Therapeutics, Inc.
|
|
|
|
|
|
|
By:
|
/s/
Alexander K. Arrow
|
|
|
|
Chief Financial
Officer
|